Cargando…
Establishment and implementation of Cancer Genomic Medicine in Japan
Approximately 1 in 2 Japanese people are estimated to be diagnosed with cancer during their lifetime. Cancer still remains the leading cause of death in Japan, therefore the government of Japan has decided to develop a better cancer control policy and launched the Cancer Genomic Medicine (CGM) progr...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935799/ https://www.ncbi.nlm.nih.gov/pubmed/33289217 http://dx.doi.org/10.1111/cas.14754 |
_version_ | 1783661070491058176 |
---|---|
author | Mukai, Yosuke Ueno, Hideki |
author_facet | Mukai, Yosuke Ueno, Hideki |
author_sort | Mukai, Yosuke |
collection | PubMed |
description | Approximately 1 in 2 Japanese people are estimated to be diagnosed with cancer during their lifetime. Cancer still remains the leading cause of death in Japan, therefore the government of Japan has decided to develop a better cancer control policy and launched the Cancer Genomic Medicine (CGM) program. The Ministry of Health, Labour, and Welfare (MHLW) held a consortium at their headquarters with leading academic authorities and the representatives of related organizations to discuss ways to advance CGM in Japan. Based on the report of the consortium, the CGM system under the national health insurance system has gradually been realized. Eleven hospitals were designated in February 2018 as core hospitals for CGM; subsequently, the MHLW built the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) as an institution to aggregate and manage genomic and clinical information on cancer patients, and support appropriate secondary use of the aggregated information to develop research aimed at medical innovation. As the first step in Japan's CGM in routine practice, in June 2019 the MHLW started reimbursement of 2 types of tumor profiling tests for advanced solid cancer patients using the national insurance system. Japan's CGM has swiftly been spreading nationwide with the collaboration of 167 hospitals and patients. The health and research authorities are expected to embody personalized cancer medicine and promote CGM utilizing state‐of‐the‐art technologies. |
format | Online Article Text |
id | pubmed-7935799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79357992021-03-15 Establishment and implementation of Cancer Genomic Medicine in Japan Mukai, Yosuke Ueno, Hideki Cancer Sci Review Articles Approximately 1 in 2 Japanese people are estimated to be diagnosed with cancer during their lifetime. Cancer still remains the leading cause of death in Japan, therefore the government of Japan has decided to develop a better cancer control policy and launched the Cancer Genomic Medicine (CGM) program. The Ministry of Health, Labour, and Welfare (MHLW) held a consortium at their headquarters with leading academic authorities and the representatives of related organizations to discuss ways to advance CGM in Japan. Based on the report of the consortium, the CGM system under the national health insurance system has gradually been realized. Eleven hospitals were designated in February 2018 as core hospitals for CGM; subsequently, the MHLW built the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) as an institution to aggregate and manage genomic and clinical information on cancer patients, and support appropriate secondary use of the aggregated information to develop research aimed at medical innovation. As the first step in Japan's CGM in routine practice, in June 2019 the MHLW started reimbursement of 2 types of tumor profiling tests for advanced solid cancer patients using the national insurance system. Japan's CGM has swiftly been spreading nationwide with the collaboration of 167 hospitals and patients. The health and research authorities are expected to embody personalized cancer medicine and promote CGM utilizing state‐of‐the‐art technologies. John Wiley and Sons Inc. 2021-02-02 2021-03 /pmc/articles/PMC7935799/ /pubmed/33289217 http://dx.doi.org/10.1111/cas.14754 Text en © 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Review Articles Mukai, Yosuke Ueno, Hideki Establishment and implementation of Cancer Genomic Medicine in Japan |
title | Establishment and implementation of Cancer Genomic Medicine in Japan |
title_full | Establishment and implementation of Cancer Genomic Medicine in Japan |
title_fullStr | Establishment and implementation of Cancer Genomic Medicine in Japan |
title_full_unstemmed | Establishment and implementation of Cancer Genomic Medicine in Japan |
title_short | Establishment and implementation of Cancer Genomic Medicine in Japan |
title_sort | establishment and implementation of cancer genomic medicine in japan |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935799/ https://www.ncbi.nlm.nih.gov/pubmed/33289217 http://dx.doi.org/10.1111/cas.14754 |
work_keys_str_mv | AT mukaiyosuke establishmentandimplementationofcancergenomicmedicineinjapan AT uenohideki establishmentandimplementationofcancergenomicmedicineinjapan |